AIM: To investigate the clinical efficacy of intravitreal injection of Conbercept in the treatment of macular edema(ME)secondary to branch retinal vein occlusion(BRVO).

METHODS: From March 2016 to May 2018, 86 patients(86 eyes)with BRVO secondary macular edema were selected. 43 patients(43 eyes)were divided into the study group and the control group. Patients in the control group were treated with intravitreal injection of razumab, while patients in the study group were treated with intravitreal injection of conbercept. The patients were followed up for 6mo. The central macular thickness(CMT)and best corrected visual acuity(BCVA)were compared before treatment(T0), 1mo after treatment(T1), 3mo after treatment(T2), 6mo after treatment(T3). The number of injections and complications were recorded during the follow-up period.

RESULTS: At 1mo, 3mo and 6mo after treatment, the levels of LogMAR BCVA(0.57±0.29, 0.42±0.21, 0.38±0.12)and CMT(343.56±46.23, 316.68±38.25, 283.56±29.47μm)in the study group were compared with those in the control group(BCVA: 0.58±0.30, 0.43±0.23, 0.40±0.13). The comparison of CMT: 345.47±46.53, 317.83±38.46, 284.34±29.56μm showed no statistical difference(PSymbol～@@0.05); the average number of injections in the study group was(2.25±1.16)times, which was significantly lower than that in the control group \〖(4.37±1.58)times, P<0.05\〗; There was no persistent ocular hypertension, endophthalmitis, retinal detachment, vitreous hemorrhage and other complications in both groups.

CONCLUSION: Vitreous injection of conbercept is effective and safe in the treatment of ME secondary to BRVO, and can significantly reduce the number of injections.